AbbVie has agreed to pay DISCO Pharmaceuticals US$40 million upfront in a research deal for "AND-gated" bispecific cancer therapies, the Cologne biotech announced on 19 November 2026. DISCO can earn up to US$2.5 billion in option, development and other milestones, plus tiered royalties, if AbbVie licenses the programmes for solid tumours.
The agreement is a collaboration with an option to license, not an outright purchase. DISCO will carry out the early research, and AbbVie can then choose to take exclusive licences to selected programmes. Neither company has named the targets, the cancers involved or how many programmes are covered, so any medicine from the deal is still at the discovery stage.
- Deal: strategic collaboration and option-to-license agreement for AND-gated bispecific therapies in solid tumours, announced by DISCO on 19 November 2026.
- Money: US$40 million in upfront payments, up to US$2.5 billion in option, development and other milestones, and tiered royalties on worldwide net sales.
- Roles: DISCO runs specified research using its DISCOtech platform; AbbVie then has the option to exclusively license selected programmes.
- Not disclosed: target pairs, cancer types, number of programmes and timelines.
- Ireland: no Irish role has been announced. AbbVie has six Irish locations, in Cork, Sligo, Mayo and Dublin.
What are the terms of the AbbVie and DISCO deal?
According to DISCO's release, dated Cologne, 19 November 2026, the two companies will work together to discover and develop AND-gated bispecific therapeutics for solid tumours with high unmet medical need. DISCO brings its DISCOtech surfaceome mapping platform and its bispecific discovery approach. AbbVie brings its global oncology research and development expertise.
The release says: "Upon successful completion of specified research activities by DISCO, AbbVie will have the option to exclusively license selected programs for further development." In practice, this means most of the headline value depends on future events. AbbVie must first decide to exercise its options, and the programmes must then pass development and commercial milestones before DISCO receives the bulk of the US$2.5 billion. Some reports round the total value differently, but the US$40 million upfront figure is the only sum that is certain today.
The release does not give closing conditions, a research timeline, the split between option fees and milestones, or the royalty rates. We found no matching AbbVie press release on its newsroom at the time of writing; the terms above come from DISCO's announcement.
| Term | Detail |
|---|---|
| Structure | Collaboration and option-to-license agreement |
| Therapy type | AND-gated bispecific therapeutics |
| Disease area | Solid tumours with high unmet medical need (specific cancers not named) |
| Upfront payments | US$40 million |
| Milestones | Up to US$2.5 billion in option, development and other milestones |
| Royalties | Tiered, on worldwide net sales (rates not disclosed) |
| DISCO's role | Specified research activities using DISCOtech |
| AbbVie's role | Option to exclusively license selected programmes for further development |
What is an AND-gated bispecific?
Most antibody medicines recognise one marker, or antigen, on the surface of a cell. The problem in solid tumours is that many of these markers also appear on healthy tissue, so a drug strong enough to kill the tumour can also damage normal organs. That limits the dose and the benefit.
A bispecific antibody has two arms that recognise two different markers. DISCO's idea is to pick pairs of markers that are found together on cancer cells but rarely together on healthy cells. The company says its approach "enables the design of bispecific antibodies that bind with high avidity only when both target antigens are simultaneously engaged on the same tumor cell, a mechanism known as AND-gating." In plain terms, the drug grips firmly only when it sees marker A and marker B on the same cell, like a lock that needs two keys.
Mark Manfredi, PhD, DISCO's chief executive, said: "Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology." He added that the platform's ability to identify tumour-selective target pairs "provides the foundation for therapies with the potential for a wider therapeutic window." A wider therapeutic window means a bigger gap between the dose that works and the dose that causes serious harm. These are company claims about a design goal; no clinical data from the AbbVie programmes exist yet.
Two formats: ADCs and T-cell engagers
DISCO says it builds two kinds of AND-gated medicine. An antibody-drug conjugate (ADC) carries a toxic payload into the cancer cell it binds. A T-cell engager links the cancer cell to the patient's own T cells so the immune system can attack it. DISCO's release does not say which format the AbbVie programmes will use.
How DISCOtech finds target pairs
DISCO describes DISCOtech as a platform that "systematically maps cancer-specific cell-surface presentation and expression patterns," with the aim of finding pairs of targets that allow highly selective tumour recognition. The cell surface proteins of a cell are known as its surfaceome, which is why DISCO calls its work surfaceome mapping.
Who is DISCO Pharmaceuticals?
DISCO Pharmaceuticals is a private biotech company based in Cologne, Germany. Its founder and first chief executive was Roman Thomas, MD. In December 2025 the company appointed Mark Manfredi as chief executive and announced the final close of a €36 million seed financing. That round was co-led by Ackermans & van Haaren and NRW.Bank, with existing investors Sofinnova Partners, AbbVie Ventures, M Ventures and Panakes Partners taking part. AbbVie's venture arm was therefore already an investor before this deal. Manfredi was previously chief executive of Ikena Oncology.
DISCO's own lead programmes are separate from the AbbVie work. The company says they are "progressing towards the clinic for small cell lung cancer and colorectal cancer". In December 2025 it described these as multiple lead ADC candidates in small cell lung cancer and microsatellite-stable colorectal cancer, moving towards the studies needed before a US investigational new drug (IND) filing.
This is DISCO's second large partnership in 2026. On 7 January 2026 it signed an exclusive licence with Amgen covering programmes against a cancer cell-surface target found with its platform. DISCO is eligible for up to US$618 million in total potential deal value plus royalties under that agreement, according to law firm Cooley, which advised DISCO.
Ajla Hrle, PhD, DISCO's chief business officer, said: "This collaboration further underscores the potential of our differentiated platform and complements our portfolio of internal and partnered pipeline programs."
How does this fit AbbVie's oncology strategy?
AbbVie says it develops targeted cancer medicines using small molecules, ADCs, immuno-oncology therapeutics, multispecific antibodies and CAR-T platforms. The DISCO agreement adds another early source of multispecific candidates to a run of similar deals:
- EvolveImmune Therapeutics, 31 October 2024: a collaboration and option-to-license agreement for multispecific T-cell engager biologics in oncology, with US$65 million in upfront fees and equity and up to US$1.4 billion in option fees and milestones.
- Ichnos Glenmark Innovation, 10 July 2025: an exclusive global licence for ISB 2001, a CD38xBCMAxCD3 trispecific antibody being studied in multiple myeloma.
- RemeGen, 12 January 2026: an exclusive licence outside Greater China for RC148, a PD-1/VEGF bispecific antibody in advanced solid tumours, with US$650 million upfront and up to US$4.95 billion in milestones.
Compared with RemeGen, where AbbVie paid for a clinical-stage asset, the DISCO deal is a much smaller upfront bet on earlier science. It follows the same option model AbbVie used with EvolveImmune: pay a modest sum now, and pay more only if the research delivers.
Is there an Irish angle?
Not directly. Neither company has linked any Irish site, trial or team to the DISCO programmes. AbbVie does have a large Irish base. RTÉ reported in September 2023 that AbbVie's manufacturing presence in Ireland dates back to 1974 and includes six separate locations, in Cork, Sligo, Mayo and Dublin. At that time AbbVie opened a €23 million European hub for supply chain, manufacturing and engineering services at Clonshaugh in north Dublin, employing close to 400 people. RTÉ also reported AbbVie's investment in Ireland over the previous ten years at more than €430 million. Our AbbVie company page lists more of its Irish activity.
Any medicine from this deal would first need years of research, clinical trials and regulatory review before Irish patients could be offered it.
Frequently asked questions
How much is the AbbVie and DISCO deal worth?
US$40 million upfront and up to US$2.5 billion in option, development and other milestones, plus tiered royalties on sales.
Which cancers will the therapies treat?
DISCO says solid tumours with high unmet need but has not named specific cancers or targets for the AbbVie programmes.
Are any of the programmes in human trials?
No. The agreement covers discovery research. AbbVie can license programmes only after DISCO completes specified research.
Will any of the work happen in Ireland?
Nothing has been announced for Ireland.
Outlook
The next points to watch are whether AbbVie exercises any options, which target pairs and cancers are chosen, and when DISCO's own ADCs for small cell lung cancer and colorectal cancer reach first human trials. Priya Life Science will report if any of this work comes to Irish trial sites or manufacturing.
Sources
- DISCO Pharmaceuticals, DISCO Pharmaceuticals announces strategic collaboration with AbbVie to develop next-generation AND-gated bispecific therapeutics for solid tumors, 19 November 2026
- Pharmaceutical Technology, AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics, 19 November 2026
- DISCO Pharmaceuticals via BioSpace, DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing, 11 December 2025, accessed 20 November 2026
- Cooley, DISCO Pharmaceuticals Enters License Agreement With Amgen, 7 January 2026, accessed 20 November 2026
- AbbVie, AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors, 12 January 2026, accessed 20 November 2026
- AbbVie, AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, 10 July 2025, accessed 20 November 2026
- AbbVie, AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option to License Agreement, 31 October 2024, accessed 20 November 2026
- RTÉ News, AbbVie opens new Dublin hub, 21 September 2023, accessed 20 November 2026
Cover image: AI-generated illustration. It is not a photograph of a real AbbVie or Disco Pharmaceuticals site or product.